Quarterly ResultJul 13, 2026, 04:42 PM
Sanuwave Preliminary Q2 Revenue $9.6-9.8M, Above Guidance
AI Summary
Sanuwave Health, Inc. announced preliminary, unaudited revenues for the second quarter of 2026 are expected to be in the range of $9.6 million to $9.8 million. This figure is above the high end of the company's revised guidance of $8.5 million to $9.5 million. However, it represents a decrease of approximately 3-5% from revenues of $10.1 million in the second quarter of 2025. Despite headwinds in capital sales, the company reported record sales for consumable applicators, indicating a promising trend for its business model.
Key Highlights
- Preliminary Q2 2026 revenue is expected to be $9.6 million to $9.8 million.
- Revenue exceeded the high end of the revised guidance of $8.5 million to $9.5 million.
- Q2 2026 revenue represents a 3-5% decrease from Q2 2025 revenue of $10.1 million.
- Capital sales faced headwinds from customer stress and sales of used Ultramist systems.
- Sales of consumable applicators set new all-time records for both unit sales and revenues.
- The company plans to report full Q2 earnings in August.
Price Impact
More from SNWV